NASDAQ:APRI Apricus Biosciences (APRI) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free APRI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3050-Day Range N/A52-Week Range$0.18▼$3.34Volume364,925 shsAverage Volume558,386 shsMarket Capitalization$8.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Apricus Biosciences alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Apricus Biosciences Stock (NASDAQ:APRI)Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. APRI Stock News HeadlinesMay 16, 2023 | finance.yahoo.comLundquist Institute Start-Up Vitalex Biosciences Awarded Grant from NIAID/NIHMay 16, 2023 | marketwatch.comErectile Dysfunction Market Analysis and Growth Foresights till 2031April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 29, 2023 | marketwatch.comErectile Dysfunction Drugs Market Market Projection and Growth Drivers 2023-2028March 11, 2023 | marketwatch.comErectile Dysfunction Drugs Market 2023-2028 Recent Study by Trend and Growth AnalysisJanuary 10, 2023 | marketwatch.comErectile Dysfunction Medicine Market : Key Player, Competition Weakness and Strengths from 2023 to 2028December 18, 2022 | marketwatch.comErectile Dysfunction Market Market Size 2023 Industry Analysis, Key Players, Regional Demand, Opportunity and Forecast 2028October 15, 2022 | marketwatch.comErectile Dysfunction Market Size From 2022 To 2029 And Unlimited Opportunities for New Companies and Latest DevelopmentsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 30, 2022 | finanznachrichten.deDiurnal Group - Proposed acquisition by Neurocrine BiosciencesSeptember 13, 2022 | markets.businessinsider.comGreat Psychedelics And Business Events Are Coming In Q4: Check Them Out HereSeptember 9, 2022 | markets.businessinsider.comSeelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics ConferenceAugust 24, 2022 | markets.businessinsider.comSeelos Receives R&D Grant From Michael J. Fox Foundation For Parkinson's Research For SLS-004August 16, 2022 | marketwatch.comAt 5.6% CAGR, Erectile Dysfunction Market Size Set to Register 7328.5 million USD by 2028August 6, 2022 | marketwatch.comErectile Dysfunction Treatment Drugs Market 2022, Worth USD 7328.5 Mn by 2028 at CAGR of 5.6% – Report Spread across 85 PagesJune 29, 2022 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of DirectorsJune 29, 2022 | apnews.comAytu BioPharma Announces the Appointment of Vivian Liu to the Company’s Board of DirectorsMarch 12, 2022 | benzinga.comErectile Dysfunction Drugs Market Grow at a CAGR of 5.0% During 2017- 2027December 20, 2021 | fool.comInvesting in Psychedelic StocksDecember 16, 2021 | markets.businessinsider.comSeelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access EventNovember 24, 2021 | markets.businessinsider.comSeelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual KetamineNovember 10, 2021 | markets.businessinsider.comSeelos Therapeutics to Present at the 4th Annual ALS ONE Research SymposiumOctober 26, 2021 | finance.yahoo.comApricus Biosciences to Present at the 2016 BIO Investor ForumOctober 1, 2021 | markets.businessinsider.comSeelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide ResearchSeptember 27, 2021 | markets.businessinsider.comWhy This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial ResultsSeptember 9, 2021 | markets.businessinsider.comSeelos Therapeutics to Participate in Two Investor Conferences in SeptemberSeptember 1, 2021 | markets.businessinsider.comSeelos Therapeutics Announces Senior Management AppointmentsSee More Headlines Receive APRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apricus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2018Today4/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:APRI CUSIPN/A CIK1017491 Webwww.apricusbio.com Phone(646) 293-2100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-216.45% Return on Assets-153.13% Debt Debt-to-Equity RatioN/A Current Ratio3.86 Quick Ratio3.86 Sales & Book Value Annual Sales$5.76 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book0.98Miscellaneous Outstanding Shares28,170,000Free FloatN/AMarket Cap$8.05 million OptionableNot Optionable Beta1.20 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesRaj MehraChairman, President, CEO & Chief Financial OfficerJessica KardishVice President-Clinical Development & OperationsLucas PilipskiExecutive Director-Clinical OperationsTim WhitakerChief Medical OfficerGopal KrishnaHead-Manufacturing & Technical OperationsKey CompetitorsAeterna ZentarisNASDAQ:AEZSAkari TherapeuticsNASDAQ:AKTXNuCanaNASDAQ:NCNAAlterity TherapeuticsNASDAQ:ATHEMolecular TemplatesNASDAQ:MTEMView All Competitors APRI Stock Analysis - Frequently Asked Questions How were Apricus Biosciences' earnings last quarter? Apricus Biosciences, Inc. (NASDAQ:APRI) released its earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. What other stocks do shareholders of Apricus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Palatin Technologies (PTN), Synergy Pharmaceuticals (SGYP), Amicus Therapeutics (FOLD), Avon Products (AVP), Chesapeake Energy (CHKAQ) and Novavax (NVAX). This page (NASDAQ:APRI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsMan Who Predicted 2008: “This Will be Worse.”AltimetryYou Won't Believe Who Bezos is Working With to Fight Alzheimer'sBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
